Halozyme Therapeutics has agreed to acquire US-based Elektrofi in a deal worth up to $900m, adding microparticle capabilities ...

While Lilly and Eisai/Biogen validated the amyloid theory in Alzheimer's disease, there are several trials of drugs with ...

AJMC: Osimertinib is an oral drug, whereas amivantamab is an intravenous formulation. Given those differences in delivery mechanisms, how do physicians need to change up workflows for the ...

Star Therapeutics has completed a Series D funding round, raising $125m, aimed at supporting its pipeline progression.

The CELEBRATE trial of the novel injectable glycoprotein IIb/IIIa inhibitor zalunfiban (Disaggpro; CeleCor Therapeutics) met ...

The FDA approved a supplemental new drug application for Tremfya for the treatment of children aged 6 years or older with ...

Treatment with Sanofi's frexalimab was seen in a study to safely maintain disease control over 2.5 years in adults with ...

Crystalys Therapeutics has emerged from its cocoon with $205 million first-round financing and a potential treatment for gout ...

After launching a multi-campus phased rollout of the predictive insulin dosing software, Philadelphia-based Temple Health’s University Hospital has reduced hypoglycemia rates two- to threefold.   The ...

At least 20 million Americans ages 40 and older have age-related macular degeneration, and the threat posed by the vision-robbing condition will only grow larger as the population ages. Despite the ...

Our annual healthcare roundtable sizes up the risks and opportunities as public policy shifts. 16 stocks to buy now.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive results from the Phase 3 HYPERION trial evaluating WINREVAIR™ (sotatercept-csrk) versus placebo (both in ...